Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Sep;66(3):474–478. doi: 10.1038/bjc.1992.298

A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.

H J Haisma 1, E Boven 1, M van Muijen 1, J de Jong 1, W J van der Vijgh 1, H M Pinedo 1
PMCID: PMC1977944  PMID: 1520585

Abstract

The anti-pan carcinoma monoclonal antibody (MAb) 323/A3, linked to E. coli-derived beta-glucuronidase (GUS) was used to study the tumour-site-selective activation of the prodrug Epirubicin-glucuronide (Epi-glu). Epi-glu was isolated from the urine of patients treated with Epirubicin (Epi) by reversed phase chromatography on a silica-C18 column. Epi-glu was stable in human blood and was not converted into Epi by A2780, MCF-7, or OVCAR-3 cancer cells, despite the presence of intracellular GUS. The stability of the prodrug was confirmed in BALB/c mice. MAb 323/A3 and GUS were linked through a stable thioether bond. The conjugate (1:1) was purified by ion exchange and gel filtration chromatography. Binding to target cells revealed an immunoreactivity of at least 60% and good retention of enzyme activity. A protein dye (sulforhodamine B) assay was used to analyse cytotoxicity. Epi (IC50 of 0.003-0.2 microM) was 100-1,000 times more toxic than Epi-glu (IC50 of greater than 20 microM), when cancer cells were exposed for 4 or 24 h to the drugs. The low cytotoxicity of Epi-glu was most likely due to the reduced cellular uptake rate of the prodrug (2.7 pmol 10(-6) cells min-1) as compared to that of the parent compound (25 pmol 10(-6) cells min-1). Pretreatment of antigen-positive cells with the 323/A3-GUS conjugate prior to prodrug exposure completely restored cytotoxicity as a result from hydrolysis of Epi-glu into Epi. Our results demonstrate that the 323/A3-GUS conjugate can specifically activate the stable non-toxic prodrug Epi-glu at the tumour cell level.

Full text

PDF
474

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagshawe K. D., Springer C. J., Searle F., Antoniw P., Sharma S. K., Melton R. G., Sherwood R. F. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 1988 Dec;58(6):700–703. doi: 10.1038/bjc.1988.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bosslet K., Czech J., Lorenz P., Sedlacek H. H., Schuermann M., Seemann G. Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br J Cancer. 1992 Feb;65(2):234–238. doi: 10.1038/bjc.1992.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cersosimo R. J., Hong W. K. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425–439. doi: 10.1200/JCO.1986.4.3.425. [DOI] [PubMed] [Google Scholar]
  4. Edwards D. P., Grzyb K. T., Dressler L. G., Mansel R. E., Zava D. T., Sledge G. W., Jr, McGuire W. L. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer. Cancer Res. 1986 Mar;46(3):1306–1317. [PubMed] [Google Scholar]
  5. Haenseler E., Esswein A., Vitols K. S., Montejano Y., Mueller B. M., Reisfeld R. A., Huennekens F. M. Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate. Biochemistry. 1992 Jan 28;31(3):891–897. doi: 10.1021/bi00118a035. [DOI] [PubMed] [Google Scholar]
  6. Haisma H. J., Boven E., van Muijen M., De Vries R., Pinedo H. M. Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol Immunother. 1992;34(5):343–348. doi: 10.1007/BF01741556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Haisma H. J., Hilgers J., Zurawski V. R., Jr Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one vial method. J Nucl Med. 1986 Dec;27(12):1890–1895. [PubMed] [Google Scholar]
  8. Hamilton T. C., Young R. C., Louie K. G., Behrens B. C., McKoy W. M., Grotzinger K. R., Ozols R. F. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 1984 Nov;44(11):5286–5290. [PubMed] [Google Scholar]
  9. Kerr D. E., Senter P. D., Burnett W. V., Hirschberg D. L., Hellström I., Hellström K. E. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol Immunother. 1990;31(4):202–206. doi: 10.1007/BF01789169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P. A., Jr Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984 Aug 3;72(1):77–89. doi: 10.1016/0022-1759(84)90435-6. [DOI] [PubMed] [Google Scholar]
  11. Maas I. W., Boven E., Pinedo H. M., Schlüper H. M., Haisma H. J. The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. Int J Cancer. 1991 Jul 9;48(5):749–756. doi: 10.1002/ijc.2910480520. [DOI] [PubMed] [Google Scholar]
  12. Mross K., Maessen P., van der Vijgh W. J., Gall H., Boven E., Pinedo H. M. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol. 1988 Mar;6(3):517–526. doi: 10.1200/JCO.1988.6.3.517. [DOI] [PubMed] [Google Scholar]
  13. Roffler S. R., Wang S. M., Chern J. W., Yeh M. Y., Tung E. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol. 1991 Oct 24;42(10):2062–2065. doi: 10.1016/0006-2952(91)90612-9. [DOI] [PubMed] [Google Scholar]
  14. Senter P. D., Saulnier M. G., Schreiber G. J., Hirschberg D. L., Brown J. P., Hellström I., Hellström K. E. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4842–4846. doi: 10.1073/pnas.85.13.4842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Soule H. D., Vazguez J., Long A., Albert S., Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973 Nov;51(5):1409–1416. doi: 10.1093/jnci/51.5.1409. [DOI] [PubMed] [Google Scholar]
  16. Tannock I. F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989 Aug 15;49(16):4373–4384. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES